NASDAQ · Financial Statements
Adamis Pharmaceuticals Corporation (ADMP) Financial Statements
$0.78
NASDAQ: ADMP
Market Cap $7.25M
Overview Financials Dividend Adamis Pharmaceuticals Corporation most recently reported annual revenue of $5.0M, a net loss of $26.0M. Revenue declined at an average annual rate of 17.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2021 2022 Revenue $15.0M $22.0M $17.0M $2.0M $5.0M Operating Profit $-39.0M $-29.0M $-37.0M $-32.0M $-25.0M Net Profit $-39.0M $-29.0M $-49.0M $-35.0M $-26.0M EPS $-69.86 $-38.52 $-44.57 $-16.80 $-12.24 Op Margin -261.6% -131.3% -225.3% -1452.0% -526.9%
Balance Sheet (USD)
Metric 2018 2019 2020 2021 2022 Total Assets $58.0M $48.0M $31.0M $38.0M $11.0M Total Liabilities $12.0M $12.0M $27.0M $12.0M $12.0M Cash $19.0M $9.0M $7.0M $23.0M $1.0M Borrowings $3.0M $4.0M $7.0M $1.0M $0
Cash Flow (USD)
Metric 2018 2019 2020 2021 2022 Operating Cash Flow $-33.0M $-20.0M $-21.0M $-38.0M $-26.0M Investing Cash Flow $-7.0M $-6.0M $-2.0M $-1.0M $3.0M Financing Cash Flow $37.0M $12.0M $20.0M $54.0M $285.0M Net Cash Flow $1.0M $-10.0M $-2.0M $17.0M $-22.0M Free Cash Flow $-36.0M $-23.0M $-22.0M $-39.0M $-27.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.03 FCF Yield -2631774.55% Quick Ratio 0.70 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .